Amylyx Pharmaceuticals (AMLX) EBIT (2021 - 2026)

Amylyx Pharmaceuticals has reported EBIT for 6 years, with the latest figure at -$45.7 million in Q2 2026.

• On a quarterly basis, EBIT fell 6.62% year-over-year to -$45.7 million in Q2 2026; TTM through Jun 2026 was -$162.1 million, a 17.7% increase from a year earlier, with the FY2025 full-year figure at -$153.3 million, up 51.29% from the prior year.
• EBIT was -$45.7 million for Q2 2026 at Amylyx Pharmaceuticals, down from -$43.8 million in the prior quarter.
• The five-year high for EBIT was $20.2 million in Q2 2023, with the low at -$122.1 million in Q1 2024.
• Average EBIT over 5 years is -$40.0 million, with a median of -$43.3 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: EBIT surged 137.23% in 2023, then slumped 5848.86% in 2024.
• Over 5 years, EBIT stood at -$44.6 million in 2022, then soared by 104.34% to $1.9 million in 2023, then sank by 2202.07% to -$40.7 million in 2024, then increased by 9.96% to -$36.6 million in 2025, then decreased by 24.83% to -$45.7 million in 2026.
• The last three EBIT figures came in at -$45.7 million (Q2 2026), -$43.8 million (Q1 2026), and -$36.6 million (Q4 2025), per Business Quant data.